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Despite efforts to reduce lead in the environ-
ment by removing lead in gasoline and ban-
ning lead-based paint, an estimated 310,000
U.S. children 1–5 years of age have elevated
blood lead levels [Centers for Disease Control
and Prevention (CDC) 2005]. In developing
countries, lead exposure is a concern because
of continued use of lead-containing products
and lack of regulations or enforcements poli-
cies (Meyer et al. 2003). Furthermore,
research suggests that lead exerts its neuro-
toxic effects in children at blood levels lower
than the current CDC action level of 10
µg/dL (Canfield et al. 2003; Jusko et al.
2008; Lanphear et al. 2005). There is grow-
ing interest in identifying host factors that
increase the risk of elevated blood lead levels
in children. Gene variants within metabolic
pathways that inﬂuence lead absorption may
be such a susceptibility factor and could place
children at increased risk of lead poisoning
even at low environmental levels (Onalaja
and Claudio 2000).
Because of the well-described inverse
relationship between iron stores and lead
absorption (Kwong et al. 2004), iron metabo-
lism genes are potential candidates to modify
lead absorption and stores. Bradman et al.
(2001) and Hammad et al. (1996) showed an
inverse relationship between dietary iron and
blood lead levels, and Wright et al. (1999,
2003) found an association between biomark-
ers of iron deﬁciency and elevated blood lead
levels both cross-sectionally and longitudinally.
Iron absorption is regulated by iron stores
and erythropoiesis (Bothwell et al. 1979) and
is influenced by dietary iron intake and
hypoxia (Morgan and Oates 2002). Hereditary
hemochromatosis (HH) is an autosomal reces-
sive disorder leading to excessive iron stores
secondary to increased intestinal iron absorp-
tion (McLaren et al. 1991). Two predominant
variants of the hemochromatosis (HFE) gene
account for most cases: the C282Y and H63D
variants, which are common in the U.S. popu-
lation, with a prevalence of 7–17% and
10–32%, respectively (Bradley et al. 1998).
Transferrin forms a stable complex with
the HFE protein to facilitate iron transfer
(Feder et al. 1998; Lee et al. 1999). It has been
suggested that the effects of HFE gene on iron
absorption depend on the complex relation-
ship between HFE and the transferrin receptor
(TfR) (Morgan and Oates 2002). Feder et al.
(1998) demonstrated that the HFE H63D
variant altered transferrin binding, leading to a
loss of HFE-repressor function for transferrin
uptake, and thereby increasing iron transport
into cells. A common missense variant of the
transferrin gene (TF) is P570S, with a preva-
lence rate of about 15% in the general popula-
tion (Lee et al. 1999).
Previous reports suggest that subjects with
clinical hemochromatosis have higher (Barton
et al. 1994) or equivalent (Åkesson et al. 2000)
blood lead levels compared with normal con-
trols. These studies were not population based,
but used case–control designs comparing adult
subjects with clinical disease with those with-
out. In a population-based cohort, our group
reported lower bone lead levels among elderly
men carrying at least one copy of H63D or
C282Y (Wright et al. 2004). The differences
in the design, sex, and age of the different
cohorts studied might account for the seem-
ingly disparate ﬁndings, with older, male sub-
jects with HFE variants being most likely to
have high body iron stores and down-regulated
lead absorption. In our 2004 report (Wright
et al. 2004), we hypothesized that variants in
iron metabolism genes might predict higher
blood lead levels in young children over time
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BACKGROUND: Given the association between iron deﬁciency and lead absorption, we hypothesized
that variants in iron metabolism genes would predict higher blood lead levels in young children.
OBJECTIVE: We examined the association between common missense variants in the hemo-
chromatosis (HFE) and transferrin (TF) genes and blood lead levels in 422 Mexican children.
METHODS: Archived umbilical cord blood samples were genotyped for HFE (H63D and C282Y)
and TF (P570S) variants. Blood lead was measured at 24, 30, 36, 42, and 48 months of age. A total
of 341 subjects had at least one follow-up blood lead level available and data available on covariates
of interest for inclusion in the longitudinal analyses. We used random-effects models to examine
the associations between genotype (HFE, TF, and combined HFE + TF) and repeated measures of
blood lead, adjusting for maternal blood lead at delivery and child’s concurrent anemia status.
RESULTS: Of 422 children genotyped, 17.7, 3.3, and 18.9% carried the HFE H63D, HFE C282Y,
and TF P570S variants, respectively. One percent of children carried both the HFE C282Y and TF
P570S variants, and 3% of children carried both the HFE H63D and TF P570S variants. On aver-
age, carriers of either the HFE (β = 0.11, p = 0.04) or TF (β = 0.10, p = 0.08) variant had blood
lead levels that were 11% and 10% higher, respectively, than wild-type subjects. In models examin-
ing the dose effect, subjects carrying both variants (β = 0.41, p = 0.006) had blood lead 50% higher
than wild-type subjects and a significantly higher odds of having a blood lead level > 10 µg/dL
(odds ratio = 18.3; 95% conﬁdence interval, 1.9–177.1).
CONCLUSIONS: Iron metabolism gene variants modify lead metabolism such that HFE variants are
associated with increased blood lead levels in young children. The joint presence of variant alleles
in the HFE and TF genes showed the greatest effect, suggesting a gene-by-gene-by-environment
interaction.
KEY WORDS: C282Y, children, H63D, hemochromatosis, iron, lead, P570S, polymorphism, trans-
ferrin. Environ Health Perspect 116:1261–1266 (2008). doi:10.1289/ehp.11233 available via
http://dx.doi.org/ [Online 24 April 2008]because of their greater dietary iron needs and
lower body iron stores, which would up-
regulate iron and lead absorption differentially
among HFE variant carriers and children with
wild-type genotypes. In this study, we sought
to determine whether genetic variants of iron
metabolism (HFE C282Y, HFE H63D, TF
P570S) were associated with blood lead levels
in children.
Materials and Methods
Study population. Study participants were
identified from among pregnant women
receiving antenatal care between 1994 and
1995 at three hospitals in Mexico City that
serve low- to middle-income populations. The
women were approached before giving birth
to participate in a randomized trial of calcium
supplementation to lower blood lead levels
over the course of lactation (Hernández-Avila
et al. 2003). Infant development was also
measured as part of this study, which was con-
ducted as part of an established interinstitu-
tional collaborative effort between researchers
in the United States (Harvard University) and
Mexico [National Institute of Public Health
and American British Cowdray (ABC)
Hospital]. The research protocol was approved
by the Human Subjects Committees of the
Harvard School of Public Health and the
National Institute of Public Health and the
participating hospitals in Mexico and has
complied with all federal guidelines governing
the use of human participants.
Data collection methods and exclusion cri-
teria have been described in detail elsewhere
(González-Cossío et al. 1997). Interviewers
explained the study to and obtained written
informed consent from eligible pregnant
women who were willing to participate.
Anthropometric data from the mother and
newborn as well as umbilical cord and mater-
nal venous blood samples were gathered
within 12 hr of delivery. Information on esti-
mated gestational age and characteristics of the
birth and newborn period was extracted from
the medical records. Baseline maternal infor-
mation on reproductive and health status,
social and demographic characteristics, risk
factors for environmental lead exposure, and
dietary assessment of nutrient intake was col-
lected from all eligible participating mothers.
Infants of participating mothers identiﬁed
before delivery had umbilical cord blood sam-
ples collected at birth (n = 520). Children were
subsequently assessed for neurocognitive devel-
opment, and blood lead levels were obtained at
24, 30, 36, 42, and 48 months of age. Data on
the neurocognitive test performance are pre-
sented elsewhere (Gomaa et al. 2002). The pre-
sent analysis is limited to data from 422 infants
who had archived umbilical cord blood avail-
able and were successfully genotyped. After
genotyping, the full data set was anonymized to
protect the conﬁdentiality of study subjects and
to conform with current institutional review
board policies. A total of 341 subjects had at
least one follow-up blood lead level available
and data available on covariates of interest for
inclusion in the longitudinal analyses.
Blood measurements. Blood lead measure-
ments were performed using graphite furnace
atomic absorption spectrophotometry (model
3000; Perkin-Elmer, Wellesley, MA, USA) at
the ABC Hospital Trace Metal Laboratory in
Mexico City according to a technique
described by Miller et al. (1987). The labora-
tory participates in the CDC blood lead proﬁ-
ciency testing program administered by the
Wisconsin State Laboratory of Hygiene
(Madison, WI, USA), which provided exter-
nal quality control specimens varying from 2
to 88 µg/dL. Our laboratory maintained
acceptable precision and accuracy over the
study period [correlation = 0.98; mean differ-
ence = 0.71 µg/dL; SD = 0.68].
Complete blood count (red blood cells,
white blood cells, hematocrit, hemoglobin,
mean corpuscular volume) in manually
diluted samples of whole blood (Beckman/
Coulter CBC-5 Hematology Analyzer; Block
Scientific Inc, Holbrook, NY, USA) and
serum ferritin (Ferritin RIA Kit, Kodak
Clinical Diagnostics, Ltd. Amersham, Bucks,
UK) were measured using standard clinical
methods at the ABC Hospital.
HFE and TF genotyping. We extracted
high-molecular-weight DNA from white blood
cells of archived umbilical cord blood with
commercially available PureGene Kits (Gentra
Systems, Minneapolis, MN, USA). After DNA
quantification, samples were adjusted to TE
buffer (containing Tris, a common pH buffer,
and EDTA, a chelating agent), partitioned into
aliquots, and stored at –80°C. Multiplex poly-
merase chain reaction (PCR) assays were
designed using Sequenom SpectroDESIGNER
software (Sequenom, Inc., San Diego, CA) by
inputting sequence containing the single
nucleotide polymorphism (SNP) site and 100
base pairs of ﬂanking sequence on either side of
the SNP. The extension product was then
spotted onto a 384-well spectroCHIP
(Sequenom, Inc.) before being flown in the
MALDI-TOF (matrix-assisted laser desorption
ionization–time of flight) mass spectrometer
(Sequenom, Inc.).
For this study, we included three SNPs:
hemochromatosis (HFE) C282Y (rs1800562)
and H63D (rs1799945) [Reference Sequence
NM_139011, GenBank (http://www.ncbi.
nlm.nih.gov/entrez/viewer.fcgi?db=
nuccore&id=91718887)], and transferrin
(TF) P570S (rs1049296) [Reference Sequence
NM_001063, GenBank (http://www.ncbi.
nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&
id=21536430)]. Specifically, the following
primers were used in the multiplex assay:
• For HFE H63D (rs1799945): forward PCR
primer, 5´-ACGTTGGATGTCTACTG-
GAAACCCATGGAG-3´; reverse PCR
primer, 5´-ACGTTGGATGTTGAAGC-
TTTGGGCTACGTG-3´; extension primer
5´-GCTGTTCGTGTTCTATGAT-3´
• For HFE C282Y (rs1800562): forward PCR
primer, 5´-ACGTTGGATGTACCCCA-
GATCACAATGAGG-3´; reverse PCR
primer, 5´-ACGTTGGATGTGGATAAC-
CTTGGCTGTACC-3´; extension primer
5´-GAAGAGCAGAGATATACGT-3´
• For TF P570S (rs1049296): forward PCR
primer, 5´-ACGTTGGATGTGAGTTG-
CTGTGCCTTGATG-3´; reverse PCR
primer, 5´-ACGTTGGATGATCTTTC-
CGTGTGACCACAG-3´; extension primer,
5´-CGCATACTCCTCCACAG-3´.
Statistical analysis. We examined distribu-
tion of HFE and TF alleles and genotypes and
tested frequencies using a chi-square statistic
to compare observed and expected counts
according to principles of Hardy–Weinberg
equilibrium. A priori the two HFE variants
(H63D and C282Y) were combined into a
single indicator term (i.e., presence of one or
two copies of either gene’s variant allele), and
subsequent analyses compared carriers of HFE
or TF variants with wild-type subjects, thus
assuming dominant effects. We calculated
summary statistics for child characteristics,
stratified by genotype. Bivariate associations
between children’s blood lead, ferritin, and
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Table 1. Genotype frequencies of children born in
Mexico City, 1994–1995. 
Genotype No. (%)
HFE C282Ya
C282Y homozygous wild type (CC) 408 (96.7)
C282Y heterozygous (CY) 14 (3.3)
C282Y homozygous variant (YY) 0 (0)
HFE H63Db
H63D homozygous wild type (HH) 345 (82.3)
H63D heterozygous (HD) 70 (16.7)
H63D homozygous variant (DD) 4 (1.0)
TF P570Sc
P570S homozygous wild type (CC) 339 (81.1)
P570S heterozygous (CT) 77 (18.4)
P570S homozygous variant (TT) 2 (0.5)
aEleven children were missing genotype data; results in
Hardy–Weinberg equilibrium: χ2 = 0.12, p = 0.73. bFourteen
children were missing genotype data; results in
Hardy–Weinberg equilibrium: χ2 = 0.05, p = 0.83. cFifteen
children were missing genotype data; results in
Hardy–Weinberg equilibrium: χ2 = 1.16, p = 0.28.
Table 2. Combined genotype frequenciesa of chil-
dren born in Mexico City, 1994–1995. 
TF genotype
Wild (CC) Variant (CT or TT)
No. (%) No. (%)
HFE genotype
Wild (CC, HH) 269 (65) 62 (15)
Variant (CY, YY, HD, DD) 65 (16) 16 (4)
aTwenty-one children were missing data on combined HFE
+ TF genotype.hemoglobin levels by genotype (wild type vs.
carrier) at each time point were compared
using Student’s t-test.
Blood lead levels followed a log-normal
distribution and were log transformed for the
analyses; thus, beta coefﬁcients from regression
models represent percent change in blood
lead. We used multivariate linear regression to
model the effect of genotype on blood lead in
cross-sectional analyses at each time point,
adjusting for maternal blood lead level at
delivery (as a measure of prenatal lead expo-
sure) and child’s concurrent anemia status (as
a marker of dietary iron intake). Anemia was
defined as a hemoglobin concentration
< 12.1 g/dL, based on recommendations for
children 2 to < 5 years of age living at an alti-
tude of 7,000–7,999 feet above sea level
(CDC 1998). We used random-effects models
with unstructured covariance to model the
association between HFE and TF genotype
and repeated measures of log-transformed
blood lead in separate models. These models
are flexible with respect to imbalance in the
data and, in addition, take into account the
correlation between repeated measures on sub-
jects. To explore a possible gene–gene interac-
tion between HFE and TF genotypes in
predicting blood lead, we modeled combined
HFE plus TF joint genotype as a dichotomous
variable (any variant present vs. both wild
type) and then, to assess allele “dose” effects,
as an ordinal variable (both variants present,
TF variant/HFE wild type, TF wild type/HFE
variant, both wild type) with wild type for
both variants as the reference group. Separate
models were repeated controlling for concur-
rent hemoglobin and concurrent ferritin to
account for potential differences in dietary
iron intake. We also constructed two-way
interaction terms between HFE and TF geno-
type, and between each gene and lead, hemo-
globin, and ferritin levels at each time point to
explore potential interactions. Finally, we used
logistic regression (PROC NLMIXED) to
examine the odds of having a blood lead level
≥ 10 µg/dL associated with presence of gene
variants. All statistical analyses were performed
using SAS software version 9.1.3 (SAS
Institute Inc., Cary, NC, USA).
Results
Four hundred twenty-two children were geno-
typed, and 17.7%, 3.3%, and 18.9% carried
the HFE H63D, HFE C282Y, and TF P570S
variants, respectively (Table 1). In addition,
1% of children carried both the HFE C282Y
and the TF P570S variants, and 3% of chil-
dren carried both the HFE H63D and the TF
P570S variants (Table 2). There were no statis-
tically significant differences in mean gesta-
tional age, sex, umbilical cord blood lead levels,
or anthropometric measures at birth between
carriers and wild-type subjects (Table 3).
Unadjusted mean blood lead levels were
consistently higher for carriers of either the
HFE or TF variant compared with wild-type
subjects at each age (24, 30, 36, 42, and
48 months), but these differences were non-
signiﬁcant (Table 4). There were no statistically
signiﬁcant differences in hemoglobin or ferritin
levels at any age between carriers and wild-type
subjects for either gene variant (results not
shown). Unadjusted mean blood lead levels of
subjects carrying any variant or both variants
(combined HFE + TF genotype) were consis-
tently higher (at any age) than subjects who
were wild type, although these differences were
also not statistically signiﬁcant (Table 4).
In cross-sectional analyses, adjusting for
maternal blood lead level at delivery and
child’s concurrent anemia status, the relation-
ship between genotype (either HFE or TF)
and blood lead level (at any age) was non-
signiﬁcant (data not shown). However, in the
longitudinal analysis (using repeated measures
of blood lead at 24, 30, 36, 42, and 48 months
of age) adjusting for covariates (maternal
blood lead level at delivery and child’s concur-
rent anemia status), the relationship between
HFE genotype and blood lead was statistically
signiﬁcant (β = 0.11, p = 0.04), and the rela-
tionship between TF genotype and blood lead
Iron metabolism genes predict children’s blood lead
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Table 3. Baseline characteristics of study population by HFE genotype and TF genotype.
HFE genotype TF genotype
All Wild type Variant Wild type Variant
Characteristic No.a Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD
Gestational age (weeks) 413 39.2 ± 1.5 329 39.2 ± 1.5 84 39.1 ± 1.4 337 39.2 ± 1.5 78 39.0 ± 1.6
Sex (% female)  414 44 330 46 84 36 338 43 78 54
Cord blood lead (µg/dL) 364 6.6 ± 3.7 289 6.6 ± 3.5 75 6.9 ± 4.2 296 6.7 ± 3.7 69 6.5 ± 3.8
Birth weight (g)  415 3,149 ± 409 331 3,164 ± 402 84 3,087 ± 433 338 3,147 ± 419 79 3,139 ± 369
Birth length (cm) 411 50.5 ± 2.3 327 50.4 ± 2.3 84 50.5 ± 2.1 335 50.5 ± 2.3 78 50.2 ± 2.1
Head circumference (cm) 399 33.9 ± 1.5 315 34.0 ± 1.5 84 33.7 ± 1.5 324 33.9 ± 1.5 77 33.9 ± 1.5
aBecause of missing data, numbers do not equal 422.
Table 4. Children’s blood lead levels (micrograms per deciliter) by age and by HFE, TF, and combined genotype (at each age).
HFE genotype TF genotype
All Wild type Variant Wild type Variant
Age (months) No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD
24  283 8.2 ± 4.4 231 8.0 ± 4.3 52 9.1 ± 4.6 227 8.0 ± 4.4 55 8.8 ± 4.4
30  167 8.4 ± 3.8 140 8.3 ± 3.9 27 9.2 ± 3.7 134 8.4 ± 3.9 34 9.3 ± 4.4
36  206 8.4 ± 5.2 164 8.2 ± 5.4 42 8.9 ± 4.1 161 8.3 ± 5.0 44 8.8 ± 5.9
42  215 8.5 ± 6.2 171 8.4 ± 6.6 44 8.7 ± 4.4 169 8.4 ± 6.6 45 9.0 ± 4.2
48  227 8.2 ± 3.8 183 8.0 ± 3.7 44 8.9 ± 4.2 179 8.1 ± 3.7 50 8.6 ± 4.1
Combined genotype
No variant  Any variant  Variant dose effect
Both wild typea HFE and/or TF variant HFE variant/TF wild TF variant/HFE wild  Both variants present
Age (months) No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD No. Mean ± SD
24  185 8.0 ± 4.5 94 8.5 ± 4.2 40 8.2 ± 4.0 45 7.9 ± 3.5 9 13.0 ± 6.0
30  110 8.2 ± 3.9 56 8.9 ± 4.2 23 9.0 ± 3.4 29 8.7 ± 3.8 4 10.6 ± 5.3
36  125 7.9 ± 3.8 77 8.6 ± 4.9 34 8.4 ± 3.5 37 8.2 ± 5.7 6 11.6 ± 6.7
42  132 8.0 ± 4.3 79 8.5 ± 3.9 35 8.1 ± 3.6 37 8.3 ± 3.5 7 12.0 ± 6.4
48  141 8.0 ± 3.8 85 8.5 ± 3.9 36 8.5 ± 3.6 41 8.0 ± 3.2 8 11.0 ± 6.1
aBoth wild type is the reference group for any variant and variant dose effect classiﬁcations.was borderline signiﬁcant (β = 0.10, p = 0.08)
(Table 5). Thus, on average, carriers of either
the HFE or TF variant had blood lead levels
that were 11% and 10% higher, respectively,
than wild-type subjects. 
There was a statistically signiﬁcant unad-
justed gene-by-gene interaction (βunadj = 0.37,
p = 0.02) between the HFE and TF genotypes
and, when adjusted for maternal blood lead
level at delivery and child’s concurrent anemia
status, this interaction term was marginally
significant (βadj = 0.31, p = 0.06) (data not
shown). There were no significant interac-
tions between either gene with concurrent
hemoglobin or with concurrent ferritin con-
centration (data not shown).
We then examined the data to explore
whether there was an interactive effect of the
presence of both HFE and TF variants on
blood lead levels. We ﬁrst examined the cross-
sectional association between having any vari-
ant present (those with HFE and/or TF
variant) versus both wild type. The dichoto-
mous combined HFE + TF genotype was not
significantly related with blood lead (at any
age) in cross-sectional models (data not
shown). Next, we defined a combined joint
genotype by grouping subjects into four cate-
gories (both variants, either HFE and/or TF
variant, both wild type) to examine the dose
effect for presence of gene variant(s). This spec-
iﬁcation did not reveal any statistically signiﬁ-
cant associations with blood lead (at any age)
in cross-sectional models (data not shown).
In longitudinal models, the result of hav-
ing any variant present (β = 0.08, p = 0.07)
was similar to having either HFE (β = 0.11,
p = 0.04) or TF (β = 0.10, p = 0.08) variant
compared with subjects who were wild type
for both variants (Table 5). When examining
the variant dose effect, compared with subjects
who were wild type for both variants, subjects
who carried both HFE + TF variants had
higher blood lead levels (β = 0.41, p = 0.006)
than subjects who carried either TF variant/
HFE wild type (β = 0.04, p = 0.5) or HFE
variant/TF wild type (β = 0.06, p = 0.3)
(Table 5). Therefore, subjects carrying both
variants had blood lead 50% higher than sub-
jects who were wild type for both HFE and
TF. These results were unchanged when
adding concurrent ferritin or concurrent
hemoglobin (in place of anemia status) as
covariates in our models (data not shown).
Figure 1 shows the risk of elevated blood
lead levels (≥ 10 µg/dL) by presence of variant
allele(s). Those subjects with either the HFE or
TF (any) variant present had significantly
higher odds of having a blood lead greater than
or equal to 10 µg/dL [odds ratio (OR) = 2.3;
95% conﬁdence interval (CI), 1.0–5.5] com-
pared with those who were wild type. Those
subjects with both variants present had signiﬁ-
cantly higher odds of having a blood lead
≥ 10 µg/dL (OR = 18.3; 95% CI, 1.9–177.1)
compared with those wild type for both HFE
and TF, though the wide CIs are attributed to
the fact that < 5% of our study population had
both variants present.
Discussion
In our current study of Mexican children, car-
riers of the HFE variant genotype had blood
lead levels 11% higher than wild-type sub-
jects. Furthermore, carriers of both HFE and
TF variant alleles had 50% higher blood lead
levels compared with wild-type subjects in
models comparing the joint effect of com-
bined HFE + TF genotype on blood lead lev-
els. Those subjects with both gene variants
present also had significantly higher odds of
having a blood lead level ≥ 10 µg/dL. Our
results suggest that genes affecting iron
metabolism also affect lead metabolism, and
this impact may be magniﬁed by the presence
of multiple genotypic variant alleles.
This is the ﬁrst study to examine the asso-
ciation between iron metabolism genes and
lead exposure in children. There are at least
three previous reports in adults or studies of
mixed ages. Barton et al. (1994) found higher
blood lead levels in subjects (children to
young/middle-aged adults) with HH com-
pared with normal controls, although they
used family history and clinical data to deter-
mine case status rather than genotype and
therefore some subjects in the control group
were likely HFE variant carriers. In another
study, Åkesson et al. (2000) found no differ-
ence in blood lead levels between adult subjects
(average age, 55.5 years) with hemochromato-
sis and controls, but found increased blood
lead levels in HH patients who had increasing
number of years of treatment by phlebotomy,
suggesting an up-regulation of absorption (due
to lowered iron stores) with a subsequent
increase in lead absorption.
In a previous population-based cohort
study (Wright et al. 2004), we found lower
blood/bone lead levels in hemochromatosis
variant (H63D or C282Y) carriers in a group of
elderly men. These results contrast particularly
with those of Barton et al. (1994). We hypothe-
sized that the results of these three studies may
have differed partly because of variations in
body iron stores, which correlate with age and
sex. Because of menstrual losses, women tend to
have lower body iron stores than men, which
would up-regulate iron/lead absorption
(Hallberg and Rossander-Hulten 1991). In
addition, because no mechanisms for iron
excretion exist, in the absence of chronic bleed-
ing disorders, iron stores tend to increase with
age. We postulated that the HFE gene effect on
blood lead level may vary by age because of
these differences in iron stores/needs that corre-
late with age/sex, and that in a younger popula-
tion with higher body iron needs, the effect of
HFE variants may be to increase lead absorption
among variant carriers. Conversely, in an older
population of elderly males, the HFE variant
effect may be attributable to down-regulation of
iron and lead absorption, because iron stores in
men are higher than in women. Our current
study supports this hypothesis; in a population
of young children with high body-iron needs,
we found higher blood lead levels among HFE
variant carriers. This study is among the ﬁrst to
present evidence that gene environment inter-
actions may vary by life stage.
In addition, our current study explored
the interactive effect of HFE + TF combined
genotype on blood lead levels in children. Our
results suggested that iron metabolism and
body lead burden are affected more pro-
foundly by the joint presence of genotypic
variant alleles in both HFE and TF. Given
the relatively small sample size to detect
Hopkins et al.
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Table 5. Longitudinal associationsa between genotype and log-transformed blood lead levels. 
Variable No. β SE p-Value
HFE variant presentb 341 0.11 0.05 0.04
TF variant presentb 341 0.10 0.06 0.08
Any variant presentb 337 0.08 0.04 0.07
Both variantsc 337 0.41 0.15 0.006
TF variant/HFE wild type 0.04 0.06 0.5
HFE variant/TF wild type 0.06 0.05 0.3
Shading indicates four separate models.
aAdjusted for maternal blood lead level at delivery and child’s concurrent anemia status. bReference group is wild-type
genotype. cReference group is wild type for both genotypes.
Figure 1. Risk of elevated blood lead levels
(≥ 10 µg/dL) by presence of variant allele. OR (and
95% CI) from nonlinear mixed-effects models
(adjusting for maternal blood lead level at delivery
and child’s concurrent anemia status; reference
group = wild type; n = 708 observations used;
n = 340 subjects; maximum number of observations
per subject = 3). Vertical lines delineate four sepa-
rate models. var, variant. 
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we used longitudinal random–effects models,
because these models are ﬂexible with respect to
imbalance in the data. We were able to include
subjects with incomplete data to increase the
power of the study to detect these effects.
There are several limitations to our study.
Our sample was restricted to a homogeneous
sample of Mexican children with a lower
prevalence of the C282Y variant (heterozy-
gotes, 3.3%) than people from Europe
(9.2%) and the Americas (9.0%), but a higher
prevalence than people from Africa/Middle
East (0.2%), the Indian subcontinent (0.5%),
Asia (0%), and Australia (0%) (Hanson et al.
2001). Therefore, because of the wide vari-
ability in prevalence rates of the C282Y vari-
ant (heterozygotes), it will be important to
replicate this study in different populations.
The potential for misclassiﬁcation should also
be considered, because there may be other
polymorphisms in the HFE or TF genes or in
a proximal gene that is in tight linkage dise-
quilibrium with these genes that could
account for our ﬁndings. Residual confound-
ing is always a concern in observational stud-
ies. We chose covariates for this analysis based
on biological plausibility as confounders (i.e.,
factors likely to be associated with both HFE
genotype and blood lead levels). Among com-
mon predictors of blood lead, few are likely
associated with HFE or TF genotype. For
example, HFE and TF are not X-linked;
therefore, sex should not be a confounder
because it is not associated with HFE or TF
genotype, and any sex-related differences due
to menstruation are not yet an issue in a pre-
pubescent population. Genotype should also
be independent of environmental lead levels.
Iron status is plausibly related to blood lead
and HFE genotype (Wright et al. 2004), but
should theoretically be a modiﬁer of the asso-
ciation of HFE with blood lead rather than a
confounder. Our results did not demonstrate
evidence of effect modiﬁcation by serum fer-
ritin or hemoglobin. Race and socioeconomic
status were accounted for in our study design,
because we enrolled Mexican children from
hospitals that serve a relatively homogeneous
group of low-to-moderate income families.
Therefore, to account for potential confound-
ing, we controlled for maternal blood lead
level at delivery (to account for differences in
prenatal lead exposure) as well as child’s con-
current anemia status (to account for differ-
ences in dietary iron intake).
With respect to the gene-by-gene interac-
tion ﬁndings, a limitation of this study is that
carriers of both variants represent < 5% of our
study population, and even though the result
is statistically significant, this could be a
chance finding. However, there is biological
plausibility to the relationship between HFE
and TF, and ours is not the ﬁrst study to ﬁnd
synergy between these two variant alleles. The
HFE gene product regulates the binding of
transferrin to transferrin receptors, which in
turn regulates the transfer of iron (and poten-
tially other transferrin-bound metals) across
cell membranes (Roy et al. 1999; Salter-Cid
et al. 1999). Furthermore, lead has been
shown to bind transferrin, down-regulating
transferrin gene expression (Adrian et al.
1993). Further evidence of this epistatic rela-
tionship is seen in clinical studies. Robson
et al. (2004) found that carriers of the C2
variant of the TF gene and the C282Y allele
of the HFE gene were at ﬁve times greater risk
for Alzheimer disease compared with all oth-
ers, whereas neither allele alone had any effect
on risk for Alzheimer disease. Although out-
side the scope of this study, Beckman et al.
(1999) examined the association between
genetic variants of iron metabolism (HFE,
TF, and the two combined) and risk for mul-
tiple myeloma, breast cancer, and colorectal
cancer. In their study, the HFE and TF geno-
types tested separately were not associated
with any of these neoplastic disorders, but
there was a significant difference between
patients and controls with respect to the two
genotypes combined. 
HFE genotype is associated with higher
blood lead levels in Mexican children over
time. Our results also suggest an interaction
between HFE and TF genotype in predicting
higher blood lead in young children. These
results differ from reports in elderly adults in
which HFE variants predicted lower blood
lead levels, demonstrating that genetic effects
differ by life stage.
In conclusion, iron deficiency has been
associated with increases in absorption and
deposition of lead (Barton et al. 1978); how-
ever, the relationship between iron and lead is
complex and not completely understood.
There is no evidence that iron supplements
themselves change lead levels after lead expo-
sure. In a randomized control trial controlling
for initial blood lead level, Mexican children
who were administered iron (or iron plus
zinc) did not have lower blood lead concen-
trations than the placebo group. Iron supple-
mentation of these lead-exposed children
signiﬁcantly improved iron status but did not
reduce blood lead levels (Rosado et al. 2006).
Based on previous research, it has been rec-
ommended that iron supplementation should
be prescribed only to iron-deﬁcient children,
regardless of blood lead levels, and not as a
treatment for lead poisoning in children
(Wright 1999). Thus, children with genetic
variants affecting iron metabolism may pre-
sent a unique challenge: They may be more
susceptible to low environmental levels of lead
exposure because of increased lead absorption
and may also be resistant to interventions
such as iron supplementation. Another study
evaluating the association between blood lead
concentration and a vitamin D receptor
(VDR) gene polymorphism found the
VDR-Fok1 variant to be an effect modiﬁer of
the relationship of floor dust lead exposure
and blood lead concentration (Haynes et al.
2003). In combination, these results highlight
that some children may be more susceptible
to lead exposure or absorption, which empha-
sizes the importance of further reducing lead
exposure to protect the most at-risk children
around the world. In addition, these children
might represent a vulnerable population that
may benefit from promising new interven-
tions such as environmental enrichment, as
deﬁned by a combination of “complex inani-
mate objects and social stimulation” (Guilarte
et al. 2003; van Praag et al. 2000). Guilarte
and colleagues exposed rats pre- and postna-
tally to lead, and then randomized them to an
enriched environment (cage with a greater
space allowance per rat, more varied toys and
ﬁxed objects, and increased human handling)
versus a standard laboratory cage with mini-
mal handling. The rats reared in the enriched
environment showed improvement in spatial
learning performance, compared with rats
reared in the standard laboratory cage, sug-
gesting the enriched environment mitigated
some of the neurotoxic effects of lead expo-
sure (Guilarte et al. 2003). These results are
particularly applicable to children, as risk fac-
tors for increased lead exposure in children
include low socioeconomic conditions such as
poor housing and decreased maternal educa-
tion. Therefore, programs aimed at defining
and providing environmental enrichment for
children at increased risk of lead exposure
might not only reduce risk but also mitigate
the neurotoxic effects of exposure.
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